Welcome to our dedicated page for Eikon Therapeutics news (Ticker: EIKN), a resource for investors and traders seeking the latest updates and insights on Eikon Therapeutics stock.
Eikon's news cycle centers on oncology clinical development and the company’s transition into the public markets. Recurring company-specific updates include progress for EIK1001 in non-small cell lung cancer, clinical evaluation of the PARP1 inhibitor candidates EIK1003 and EIK1004, development work around the WRN helicase inhibitor EIK1005, and corporate financing milestones tied to its initial public offering.
For Eikon Therapeutics, future news is most useful when read through the lens of pipeline advancement and funding capacity. Investors can compare whether updates show movement in named clinical programs, whether combination strategies remain feasible, and how financial results relate to the cost of advancing multiple oncology candidates.
Eikon Therapeutics (Nasdaq: EIKN) reported corporate and clinical updates on March 30, 2026, including a closed upsized IPO raising $381.2 million and a cash, cash equivalents and marketable securities balance of $336.0 million as of December 31, 2025. The company expects cash to fund operations into the second half of 2027.
Clinical progress: completed enrollment in the TeLuRide-005 Phase 2 trial of EIK1001 with data expected in 2H 2026; EIK1003 and EIK1004 Phase 1/2 programs advancing with a cohort start anticipated in 2H 2026; EIK1005 healthy volunteer study completed and patient trial underway. Financials show year-over-year increases in R&D and G&A and a 2025 net loss of $333.6 million.
Eikon Therapeutics (Nasdaq:EIKN) priced an upsized initial public offering of 21,177,600 shares at $18.00 per share, with gross proceeds expected to be approximately $381 million before fees. The underwriters have a 30-day option for an additional 3,176,640 shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on February 5, 2026, with the offering scheduled to close on or about February 6, 2026, subject to customary closing conditions.